Default company panoramic image
Logo

TriMod Therapeutics Ltd

Combining two medicines - a TLR agonist and a Kinase Inhibitor - mobilises the powerful immune system to target and eradicate cancers.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Dublin, Ierland
  • Currency EUR
  • Founded May 2011
  • Employees 3
  • Website trimodtherapeutics.com

Company Summary

TriMod is a seed-capital funded Biotechnology company. Founded on ground-breaking and patented science, we are developing a combination therapy that enables the immune system to seek out and destroy existing tumours. Efficacy has been seen in pre-clinical in vivo models of Melanoma, Colon and Lung cancers. Using our seed capital we have identified optimal human-ready molecules. Using Series A financing of €7.5 will be testing in patients in 2014.

Team

  • Default avatar
    Jeremy Skillington, PhD
    CEO

    A recognised Biotechnology business leader, Jeremy has spent over 10 years in the industry. Starting in Business Development at Genentech, Inc, Jeremy executed over 35 licensing and collaboration transactions. He then led Business Development at Opsona Therapeutics prior to co-founding TriMod in 2011.

    Jeremy’s business acumen is underpinned by strong scientific training at the University of California, San Francisco and NUI Galway (Ireland).

  • Default avatar
    Prof Kingston Mills
    Director

    Prof Mills is a globally recognized and distinguished leader in the field of Immunology and brings over 30 years of academic (TCD, University College London, NUI Maynooth) and entrepreneurial (Co-Founder of Opsona Therapeutics) excellence to TriMod. Prof Mills has published ›170 peer-reviewed articles, is co-inventor on 14 patents and applications, is Director of the Immunology Research Centre at TCD and is a member of the Royal Irish Academy.

  • Default avatar
    Dr Bernd Seizinger
    Acting Chairman

    Dr Seizinger is currently Executive Chairman of Opsona Therapeutics and brings extensive Oncology and Industry Experience (GPC Biotech (CEO), Genome Therapeutics (CSO) and Bristol-Myers Squibb (VP Oncology Drug Discovery)) as well as Academic expertise (Harvard, Princeton, Max Planck) to TriMod. He is the recipient of a number of scientific awards and has authored over one hundred publications.

  • Default avatar
    Prof John Armstrong
    Director

    Professor Armstrong is a Consultant Radiation Oncologist and is a Board Member and ex-chairman of the Irish Cancer Society. Prof Armstrong trained and was Chief Resident at MSKCC. Prof Armstrong is currently Director of Research at St. Lukes Hospital, Dublin. He was a founding member and past chairman of the Irish Clinical Oncology Research Group and is the PI for several clinical trials. He is Medical Director for UPMC Cancer Centres Ireland.

Advisors

  • Default avatar
    Martin Kelleher, Senior Corporate Partner, Mason Hayes Curran
    Lawyer
    Unconfirmed
    Default avatar
    Alan Lawlor, Partner, Wallace O'Donoghue
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Oyster Technology Investments, Ltd
    Unconfirmed
    Default avatar
    Enterprise Ireland
    Unconfirmed
    Default avatar
    Opsona Therapeutics Ltd
    Unconfirmed